RELATED CONTENT
NEWS
- AAN 2013 preview: no game changers but pipeline developments aplenty
- Q2 pharma results preview: Currencies and euro-austerity pain to dominate
- ALS patients, advocates urge shorter trials, expanded access for experimental medicines
- Baxter drug joins group of high-profile Alzheimer's failures

